BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

BridgeBio Pharma, Inc.

BridgeBio finds, develops, and delivers breakthrough medicines for genetic diseases.

Millions worldwide are afflicted with genetic diseases, but small patient populations and industry reluctance to conduct early-stage development means that for many, treatments have not been forthcoming. We are committed to bridging this gap: between business case and scientific possibility, between patient and hope. BridgeBio creates a bridge from remarkable advancements in genetic science to patients with unmet needs via the entrepreneurial engine required to make life-changing medicines as rapidly as possible.

BridgeBio is committed to developing leaders as well as drugs. We are looking for individuals whose passion for creating life-changing medicines will inspire hands-on engagement and the dogged pursuit of novel solutions in the face of adversity.

MyoKardia

Eidos Therapeutics

Blue Owl

CPP Investments

Qatar Investment Authority

Perceptive Advisors

Janus Fund

Viking Global Investors

Cormorant Capital

Kohlberg Kravis Roberts

Hercules Capital

AIG Investments

Sequoia Capital

Aisling Capital

BridgeBio

Our chief medical officer at BridgeBio Gene Therapy, 👤 Adam Shaywitz, M.D., Ph.D., will chair a panel today at the PMWC - Precision Medicine World Conference on novel clinical design approaches in rare diseases. Learn more about his session here: https://bit.ly/3vwZsdq

This week Dunni Odumosu, MS, vice president of regulatory affairs at BridgeBio Gene Therapy will lead a workshop at the Gene Therapy Regulatory Affairs Summit on the key learnings and best practices for optimizing regulatory interactions in the rapidly evolving field of gene therapy. Check out the agenda: https://bit.ly/3TWKJTs

In our latest episode of #OnRare we were privileged to speak with Effie Parks, a rare mom, a patient advocate, a podcaster, and host of “Once Upon a Gene.” Effie candidly shares her experience of being a new mom to a child living with a rare condition and her journey into the advocacy space. https://bit.ly/47H0S2q

We appreciate the partnership with the limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) advocacy groups and applaud their many achievements. We are excited to continue working on behalf of the LGMD community and to see what is next for 2024. Together We Are Stronger!

We are proud to share that the positive results from our Phase 3 ATTRibute-CM study have been published in the NEJM Group. We submitted our New Drug Application for acoramidis to the U.S. FDA in 2023 and intend to submit additional marketing authorization applications to regulatory bodies this year. Learn more: https://bit.ly/3TPN8iF

Thank you JPMorgan Chase & Co. for inviting us to present at the Annual Healthcare Conference! Our CEO and founder, Neil Kumar, Ph.D. shared our learnings across the ATTR-CM space since last year as well as provided updates on our late-stage programs, our research & early development candidates, and our priorities for 2024. #JPM24 Listen to our presentation here: https://bit.ly/3H3uL2b

To wrap up our 2023, our On Rare team recalled the wonderful, rare conversations we held with our extraordinary guests. Join us for a look back at 2023 and don’t forget to subscribe to learn more from our guests in 2024. https://bit.ly/3tL5rLd

BridgeBio founder & CEO Neil Kumar, Ph.D. is presenting at the J.P. Morgan 42nd Annual Healthcare Conference today at 8:15 a.m. PT. Join and learn about our goal to develop medicines for people with genetic diseases and cancers. Listen to the presentation here: https://bit.ly/3H3uL2b

We are on a mission to discover, create, test, and deliver transformative medicines to treat patients with genetic diseases and cancers. Learn more about our upcoming presentation at the J.P. Morgan Annual Healthcare Conference, where we will discuss our milestones for the year. Read more: https://bit.ly/3H6969k

The U.S. FDA has cleared our investigational new drug (IND) application for BBO-8520, a first-in-class orally bioavailable and potentially highly potent small molecule direct inhibitor of KRASG12C. We intend to begin enrollment of patients with KRASG12C mutant non-small cell lung cancer into our ONKORAS-101 trial, which is expected to begin in the first half of this year. Learn more: https://bit.ly/3H5JyJB

	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables	1.89M -	13.51M 616.66%	8.85M 34.47%	8.95M 1.05%	11.88M 32.86%	11.56M 2.74%	10.65M 7.81%
accumulated other comprehensive income loss	-27K -	-231K 755.56%	254K 209.96%	192K 24.41%	-132K 168.75%	-328K 148.48%	31K 109.45%
cash and cash equivalents	92.00M -	436.09M 374.03%	363.77M 16.58%	356.08M 2.11%	393.77M 10.58%	376.69M 4.34%	375.94M 0.20%
cash and short term investments	92.00M -	436.09M 374.03%	577.14M 32.34%	607.09M 5.19%	787.51M 29.72%	428.27M 45.62%	434.88M 1.54%
common stock	3.41M -	6.59M 93.32%	124K 98.12%	125K 0.81%	154K 23.20%	157K 1.95%	181K 15.29%
deferred revenue			31.45M -	75.90M 141.30%		8.16M -	6.10M 25.26%
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets					44.93M -	28.71M 36.10%	26.32M 8.33%
intangible assets					44.93M -	28.71M 36.10%	26.32M 8.33%
inventory					-68.90M -	37.93M 155.05%	16.65M 56.10%
long term debt		54.51M -	99.79M 83.08%	494.33M 395.36%	1.73B 249.19%	1.72B 0.15%	1.74B 0.70%
long term investments		17.05M -	31.14M 82.66%		49.15M -	43.65M 11.18%	3.74M 91.42%
net debt	-92.00M -	-381.58M 314.78%	-263.98M 30.82%	139.71M 152.92%	1.33B 853.72%	1.35B 1.09%	1.36B 1.26%
net receivables					19.75M -	17.08M 13.52%	1.75M 89.75%
other assets
other current assets	889K -	2.05M 130.60%	22.63M 1,003.85%	35.73M 57.90%	101.34M 183.63%	21.92M 78.37%	24.30M 10.87%
other current liabilities	6.67M -	19.07M 186.09%	4.08M 78.61%	5.55M 36.10%	113.31M 1,941.60%	94.36M 16.72%	122.97M 30.31%
other liabilities
other non current assets	473K -	1.09M 131.08%	-4.86M 544.28%	23.93M 592.81%	33.03M 38.01%	20.22M 38.77%	22.63M 11.87%
other non current liabilities	144.18M -	479.36M 232.48%	3.53M 99.26%	9.52M 169.92%	22.07M 131.82%	26.64M 20.73%	9.36M 64.87%
othertotal stockholders equity	-806K -	109K 113.52%	845.86M 775,922.02%	946.34M 11.88%	566.53M 40.13%	663.70M 17.15%	1.21B 81.71%
preferred stock	833K -	122K 85.35%	2.24M 1,738.52%
property plant equipment net	440K -	1.57M 257.95%	5.63M 257.14%	36.83M 554.81%	45.97M 24.81%	25.25M 45.08%	19.84M 21.40%
retained earnings	-61.43M -	-170.58M 177.70%	-440.03M 157.96%	-888.75M 101.98%	-1.44B 61.68%	-1.92B 33.49%	-2.56B 33.49%
short term debt			8M -	1.46M 81.77%	4.94M 238.68%	3.67M 25.58%	4.13M 12.33%
short term investments			182.22M -	251.01M 37.75%	442.89M 76.44%	95.23M 78.50%	58.95M 38.10%
tax assets							-3.74M -
tax payables
total assets	98.04M -	464.94M 374.22%	631.68M 35.86%	703.59M 11.38%	1.01B 43.95%	623.04M 38.48%	546.38M 12.30%
total current assets	97.13M -	445.22M 358.37%	599.77M 34.71%	642.82M 7.18%	839.71M 30.63%	505.20M 39.84%	477.59M 5.46%
total current liabilities	8.55M -	32.58M 281.02%	52.38M 60.80%	91.85M 75.34%	130.13M 41.67%	117.75M 9.51%	143.84M 22.16%
total debt		54.51M -	99.79M 83.08%	495.79M 396.83%	1.73B 248.17%	1.72B 0.15%	1.74B 0.94%
total investments		17.05M -	182.22M 968.74%	251.01M 37.75%	492.04M 96.02%	138.89M 71.77%	58.95M 57.56%
total liabilities	152.73M -	566.44M 270.88%	155.70M 72.51%	595.70M 282.59%	1.88B 215.32%	1.87B 0.55%	1.89B 1.12%
total liabilities and stockholders equity	98.04M -	464.94M 374.22%	631.68M 35.86%	703.59M 11.38%	1.01B 43.95%	623.04M 38.48%	546.38M 12.30%
total non current assets	913K -	19.72M 2,059.69%	31.91M 61.85%	60.76M 90.41%	173.08M 184.84%	117.84M 31.92%	68.79M 41.62%
total non current liabilities	144.18M -	533.87M 270.28%	103.32M 80.65%	503.85M 387.67%	1.75B 246.98%	1.75B 0.11%	1.75B 0.29%
total stockholders equity	-58.02M -	-163.99M 182.66%	408.45M 349.08%	57.91M 85.82%	-870.41M 1,603.15%	-1.25B 44.14%	-1.35B 7.94%

COM:BRIDGEBIO

BridgeBio Pharma, Inc.

Last Close

23.24

22/11 21:00

Market Cap

4.97B

Beta: -

Volume Today

2.05M

Avg: -

Preview